Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Gain Therapeutics Inc GANX

Gain Therapeutics, Inc. is a biotechnology company. The Company is focused on developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company’s drug... see more

NDAQ:GANX - Post Discussion

Gain Therapeutics Inc > S&P 500 Edges Lower; RH Shares Plunge After Q1 Results | Ben
View:
Post by whytestocks on Jun 14, 2024 5:15pm

S&P 500 Edges Lower; RH Shares Plunge After Q1 Results | Ben

News; $GANX S&P 500 Edges Lower; RH Shares Plunge After Q1 Results | BenzingaU.S. stocks traded mixed toward the trading, with the Dow Jones index falling around 0.2% on Friday.The Dow traded down 0.24% to 38,554.69 while t...GANX - S&P 500 Edges Lower; RH Shares Plunge After Q1 Results | Benzinga
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities